Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes

Abstract Colistimethate sodium (CMS) is increasingly used to treat multidrug-resistant Gram-negative bacilli infections. However, the incidence of CMS-associated nephrotoxicity has not been evaluated in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia. This retrospective study included 120 patients with CRAB pneumonia treated with intravenous CMS for ≥72 h. The objective of the study was to determine risk factors for CMS-induced nephrotoxicity and 30-day mortality in patients with CRAB pneumonia. Of the 120 patients with CRAB pneumonia, 61 (51%) developed nephrotoxicity. Multivariate analysis showed that dose per ideal body weight (IBW) [odds ratio (OR) = 1.28, 95% confidence interval (CI) 1.01−1.62; P  = 0.04], Charlson co-morbidity index (OR = 1.31, 95% CI 1.06–1.60; P  = 0.01) and septic shock (OR = 3.16, 95% CI 1.32–7.60; P  = 0.01) were associated with CMS-associated nephrotoxicity. Thirty-day mortality was 33% (39/120). Multivariate analysis showed that higher daily doses of CMS per IBW [hazard ratio (HR) = 0.81, 95% CI 0.67–0.98; P  = 0.03] and longer duration of CMS therapy (HR = 0.86, 95% CI 0.79–0.95; P  = 0.002) were associated with increased survival. Septic shock (HR = 3.91, 95% CI 1.95–7.83; P P  = 0.001) were associated with decreased survival in patients with CRAB pneumonia. Higher daily doses of CMS per IBW, Charlson comorbidity index and septic shock were significant risk factors for CMS-associated nephrotoxicity. However, CMS-associated nephrotoxicity does not appear to have an impact on mortality.